

NOVEMBER 19, 2020

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China

NEW YORK & SHANGHAI & PRINCETON, N.J. - November 19, 2020 – Pfizer, Inc. (NYSE: PFE) and LianBio announced today that they have entered into a collaboration aimed at developing and commercializing transformative pharmaceutical products in Greater China. LianBio, founded by Perceptive Advisors, forged a collaboration with Pfizer to pursue an innovative business development opportunity. Both companies will be dedicated to advancing best-in-class therapies for patients, leveraging both LianBio’s and Pfizer’s clinical development, regulatory and commercial expertise.

“We are honored to partner with Pfizer, a significant pioneer in the industry, to build upon their extensive commercial engine in Greater China, as well as tap into their relationships with leading physicians specializing in a broad range of therapeutic areas,” said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman of LianBio. “LianBio’s well-established sourcing capabilities, derived from Perceptive Advisors and other world class investors, will enable our partnership to bring precision-based medicines to patients in Greater China. This deal also provides LianBio additional non-dilutive funding to build out and advance our robust and diverse pipeline of innovative therapies targeting a variety of diseases.”

Pierre Gaudreault, President of Pfizer Biopharmaceuticals Group, China, said, “Pfizer’s purpose is breakthroughs that change patients’ lives. To fulfill our purpose, we must be able to get our innovative medicines and vaccines into the hands of patients who need them. Through this partnership with LianBio, we will be able to expand access to innovative medicines in Greater China and address unmet patient needs.”

“Pfizer shares a vision with LianBio and their founders, Perceptive Advisors: driving development of and access to best-in-class medical breakthroughs across the China market. Consistent with this vision, our new strategic alliance with LianBio will expand our ability to partner across the biotech ecosystem and enable us to deliver important medical innovations to patients in China,” said Doug Giordano, Senior Vice President, Pfizer Worldwide Business Development.

In addition to Pfizer’s participation in LianBio’s recent crossover financing, under the terms of the collaboration, Pfizer will contribute up to \$70M of non-dilutive capital toward in-licensing and co-development. At LianBio’s discretion, products will be presented to Pfizer for joint development. Pfizer will have a right of first negotiation to obtain commercial rights to jointly developed assets and each will carry separate financial considerations. During the collaboration, Pfizer may provide in-kind support for marketing, development and regulatory activities.

About LianBio

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with

transformative mechanisms and precision-based therapeutics. For more information, please visit www.lianbio.com.

Pfizer Inc: Breakthroughs that change patients' lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com.cn.

LianBio

Investor Contact:

Thomas Hoffmann

Solebury Trout

[646-378-2931](tel:646-378-2931)

thoffmann@soleburytrout.com

Media Contact:

Hannah Gendel

Solebury Trout

[646-378-2943](tel:646-378-2943)

hgendel@soleburytrout.com

Pfizer

Media Contact:

Trupti Deepak Wagh

[+65 9187-3247](tel:+65-9187-3247)

trupti.wagh@pfizer.com

SEE ALL NEWS

About

Who We Are

Management Team

Board of Directors

Our Investors

Program Partners

Pipeline

Cardiorenal

Oncology

